NeuroSense Therapeutics Ltd. — Company profile
Healthcare · Biotechnology · Israel
Last price 1.99 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Details
| Name | NeuroSense Therapeutics Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 17 |
| Founded | 2017 |
| Ipo Date | 2021-12-09 |
| Ceo | Alon Ben-Noon |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 6.00 |
| Isin | IL0011809592 |
| Cik | 1875091 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Alon Ben-Noon | Co-Founder, Chief Executive Officer and Director |
| Or Eisenberg | Chief Financial Officer |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer |
Contact
| Address | Building B, 11 HaMenofim Street, Herzliya, 4672562, Israel |
| Phone | 972 9 799 6183 |
| Website | https://www.neurosense-tx.com |